MECOM and Miyoshi myopathy: As shown in Fig. 5F, MB treatment reduced the protein levels of RUNX1, CDK6, PU.1, c-Myc, EVI1, HOXA9, MEIS1, BFL1 and MCL1 in phenotypically-defined FPD-MM myeloid stem-progenitor cells [26, 27].